Clin2
NCT06764966Possibly a fitRecruiting

Statin and beta blocker study for liver disease

Decompensated Liver CirrhosisCirrhosisDecompensated Cirrhosis of LiverDecompensated Cirrhosis and Ascites

Treatments studied

Part of Digestive system, Heart & circulation clinical trials.

This trial tests if adding a statin to beta blocker treatment helps people with advanced liver disease (cirrhosis) who have had complications like fluid buildup, confusion, or bleeding. It is for patients who are already taking a non-selective beta blocker and will be followed for 12 months.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older
  • You must have decompensated cirrhosis (with swelling in the belly, confusion episodes, or variceal bleeding)
  • You must already be taking a non-selective beta blocker for your liver condition
  • You must agree to get your liver care at the CAMC Liver Clinic for 12 months
  • You cannot currently take a statin
  • You must not have liver cancer, be on a transplant list, or have ongoing alcohol use (more than one drink per week)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05028829Recruiting· Phase 2
Atorvastatin to lower liver cancer risk in people with liver scarring

This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.

Boston, Massachusetts
NCT05832229Recruiting· Phase 2
Studying rosuvastatin to slow liver scarring in cirrhosis

This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.

La Jolla, California
NCT06549673Recruiting
Stopping beta blocker in controlled cirrhosis

This study is checking if it is safe for people with cirrhosis (liver scarring) to stop taking a certain blood pressure medicine (non-selective beta blockers) if their main liver problem is under control. If you've had varices or bleeding in the past and your liver is now stable, this trial will see if you can safely stop the medicine.

Sydney
NCT06855056Recruiting
Studying new markers for recovery from liver cirrhosis complications

This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.

Clichy, France
NCT06431919Recruiting
Adding statin to carvedilol for cirrhosis with heart problems

This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.

Chandigarh
NCT04971577Recruiting· Phase 2/Phase 3
Simvastatin for alcohol-related liver scarring in stable adults

This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.

Barcelona

Hear when a new Decompensated Liver Cirrhosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.